| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 64,897 | 81,659 | ||
| Marketable securities | 421,301 | 444,921 | ||
| Prepaid expenses and other current assets | 18,406 | 12,252 | ||
| Total current assets | 504,604 | 538,832 | ||
| Other non-current assets | 0 | 0 | ||
| Total assets | 504,604 | 538,832 | ||
| Accounts payable-Nonrelated Party | 7,457 | 3,712 | ||
| Cvr liability | 11,020 | 59,900 | ||
| Accrued and other current liabilities | 23,827 | 19,416 | ||
| Related party accounts payable-Related Party | 3,970 | 31 | ||
| Total current liabilities | 46,274 | 83,059 | ||
| Non-current cvr liability | 3,230 | 0 | ||
| Total liabilities | 49,504 | 83,059 | ||
| Series a non-voting convertible preferred stock & preferred stock shares authorized, issued, and outstanding, value-Series ANon Voting Convertible Preferred Stock | 146,425 | 146,425 | ||
| Series a non-voting convertible preferred stock & preferred stock shares authorized, issued, and outstanding, value-Series BNon Voting Convertible Preferred Stock | 9,395 | 9,395 | ||
| Series a non-voting convertible preferred stock & preferred stock shares authorized, issued, and outstanding, value-Preferred Stock Excluding Series AAnd BNon Voting Convertible Preferred Stock | 0 | 0 | ||
| Common stock, 0.0001 par value 400,000,000 shares authorized as of september30, 2025 and december31, 2024 60,471,793 shares and 60,257,023 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 13 | 13 | ||
| Additional paid-in capital | 1,363,581 | 1,353,408 | ||
| Accumulated other comprehensive income | 791 | 454 | ||
| Accumulated deficit | -1,065,105 | -1,053,922 | ||
| Total stockholders equity | 455,100 | 455,773 | ||
| Total liabilities, convertible preferred stock and stockholders equity | 504,604 | 538,832 | ||
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)